TX-SPINALCYTE,-LLC
15.5.2019 16:20:11 CEST | Business Wire | Press release
SpinalCyte, LLC, a clinical stage regenerative medicine company focused on regrowth of the spinal disc using Human Dermal Fibroblasts (HDFs), today announced a new comprehensive resource to raise awareness of the potential benefits of fibroblasts and provide a growing knowledge base for this promising regenerative medicine technology.
The company’s website, www.spinalcyte.com , now features company and independent research studies demonstrating the potential of this new cell source for disc repair and other disease pathways.
“Fibroblasts hold significant advantages over mesenchymal stem cells,” said Dr. Thomas Ichim, Chief Scientific Officer of SpinalCyte and author of an analysis comparing the two cell sources published in the Journal of Translational Medicine . “As we and other leading researchers continue to advance the science in this field, our website will be the best place to find the latest and most up-to-date information on the healing power of fibroblasts.”
SpinalCyte is the leader in the field of HDF therapy with 52 U.S. and international patents issued and 85+ patents pending focused on the clinical utility of fibroblasts.
“Fibroblasts are the regenerative cell source of the future,” said Pete O’Heeron, Chief Executive Officer of SpinalCyte. “The breadth of our intellectual property demonstrates the versatility of this technology and positions us as the unquestioned frontrunner in this emerging sector. We look forward to presenting new research from around the globe highlighting the promise of fibroblasts.”
About Degenerative Disc Disease
Degenerative disc disease (DDD) is a condition in which a patient’s spinal disc breaks down and can begin to collapse. It is estimated that 85% of people over the age of 50 have evidence of disc degeneration and over 1.3 million procedures a year are performed to treat the disease. The most common treatments for patients with DDD are either discectomy or spinal fusion. Discectomy is the partial or full removal of the degenerated disc to decompress and relieve the nervous system but can cause long term spinal pain. In a spinal fusion procedure, the entire disc is removed and the two adjacent vertebrae are fused together. It often increases strain on the adjacent discs and surrounding tissues leading to further degeneration.
About CybroCell
CybroCell is the first off-the-shelf allogenic human dermal fibroblast (HDF) product for the treatment of degenerative disc disease. SpinalCyte’s Phase 1/Phase 2 clinical trial for injected human dermal fibroblasts in the treatment of DDD demonstrated after 18 months, patients injected with CybroCell had sustained improvement in pain relief and increased back mobility.
About SpinalCyte
Based in Houston, Texas, SpinalCyte, LLC, is a regenerative medicine company developing an innovative solution for spinal disc replacement using human dermal fibroblasts. Currently, SpinalCyte holds 52 U.S. and international issued patents and has filed for an additional 85+ patents pending and issued across a variety of clinical pathways, including disc degeneration, cancer, diabetes, liver failure and heart failure. SpinalCyte represents the next generation of medical advancement in cell therapy. Visit www.spinalcyte.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20190515005305/en/
Contact:
David Schull or Ned Berkowitz Russo Partners LLC 858-717-2310 646-942-5629 david.schull@russopartnersllc.com ned.berkowitz@russopartnersllc.com
Clinical Contact: info@spinalcyte.com
Link:
Social Media:
https://www.facebook.com/LibertyStarLBSR/#!/pages/Liberty-Star-Uranium-Metals-Corp/135810219778400?r
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ZincFive Expands Nickel-Zinc Technology into In-Rack Backup and AI Dynamic Power Solutions28.9.2026 14:05:00 CEST | Press release
Applying proven high-rate nickel-zinc technology to in-rack backup and AI-driven transient power applications ZincFive®, the leader in nickel-zinc (NiZn) battery-based solutions for immediate power applications, today announced its expansion into in-rack energy storage with the development of Battery Backup Unit (BBU) and AI Dynamic Power Module (DPM) solutions designed to address the evolving energy storage requirements of AI data centers. As AI drives higher rack power densities and increasingly dynamic workloads, data center power architectures are evolving to manage both traditional backup requirements and rapid, repeated changes in power demand. These transient loads can place significant stress on electrical infrastructure, creating a growing need for power solutions closer to the rack that can respond quickly, safely, and reliably. Today’s rack-level technologies often require tradeoffs between energy capacity and dynamic power response. Traditional BBUs are primarily designed t
Oscilloquartz and Iridium expand resilient positioning and navigation capabilities with new PNT service integration28.9.2026 14:00:00 CEST | Press release
News summary: Defense and critical infrastructure require resilient PNT architectures that maintain trusted timing and positioning during GNSS loss Oscilloquartz is expanding Iridium® PNT (formerly Iridium STL®) support across its portfolio, enabling customers to leverage resilient positioning and navigation alongside trusted timing across more applications Collaboration strengthens multi-layered assured PNT architectures by combining Oscilloquartz’s timing portfolio with Iridium satellite services Oscilloquartz today announced the next phase of its collaboration with Iridium Communications Inc., expanding the range of Iridium® positioning, navigation and timing (PNT) (formerly Iridium Satellite Time and Location® or STL®) capabilities available across its synchronization portfolio. The latest integration brings resilient positioning and navigation alongside trusted timing to a broader range of applications. Building on the companies’ existing collaboration, it strengthens end-to-end,
Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 3 AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta Virus28.9.2026 14:00:00 CEST | Press release
– Phase 3 primary endpoint (virologic response and ALT normalization) achieved in both dose arms at Week 24– 48-week data from Phase 2b portion of AZURE-1 demonstrate deepening viral suppression and increased rates of ALT normalization with longer-term treatment– Favorable safety and tolerability profiles observed; no new safety signals– Mirum to host conference call to discuss topline results today, September 28, at 8:30 a.m. ET Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced the primary endpoint was met in the Phase 3 portion of the AZURE-1 study evaluating brelovitug, an investigational fully human monoclonal antibody that binds to hepatitis B surface antigen (HBsAg), for the treatment of chronic hepatitis delta virus (HDV). In addition, 48-week data from the Phase 2b portion of AZURE-1 demonstrated deepening viral suppression, with a greater proportion of patients achieving HDV RNA below the lower limit of quantification (LLOQ, <10 IU/mL)
Mirion Technologies to Host Inaugural Mirion Connect EMEA/APAC Conference in Brussels28.9.2026 14:00:00 CEST | Press release
Mirion Connect 2026 EMEA/APAC is Mirion Technologies’ first regional nuclear and radiation safety technology conference for Europe, the Middle East, Africa and Asia-Pacific.The conference expands the US-based Mirion Connect event, bringing together experts and technology users across nuclear safety, measurement technologies and radiation science for training, industry forums, product demonstrations and more.Featured speakers will cover topics like radiopharmaceutical advancements, nuclear energy expansion, global environmental testing and capacity-building, and growth in small modular reactor technology Mirion Technologies, a leading provider of advanced radiation safety solutions, today announced Mirion Connect 2026 EMEA/APAC, the company’s first regional edition of its Mirion Connect conference for Europe, the Middle East, Africa and Asia-Pacific region. The event will take place September 29 – October 1, 2026, in Brussels, Belgium. Mirion Connect, an event hosted in the United State
Xceedance Reports 35-50% Efficiency Gains in Insurance Operations Through AI Orchestration28.9.2026 14:00:00 CEST | Press release
Production deployments on Xceedance’s agent studio have delivered approximately 35% efficiency improvements at go-live, with some early implementations approaching 50% through ongoing optimization and operational learning. Xceedance said today that AI orchestration is producing measurable efficiency gains in live insurance operations, delivered through Orchestrated Intelligence, its operating model, and IAN, its agent studio for insurance. In agency and broker operations, processes moved onto IAN delivered around 35% efficiency improvement from the point of go-live. As these implementations have matured, some are now approaching 50%. Xceedance is seeing the same pattern in underwriting support for excess and surplus lines carriers. The company is also deploying AI at scale in claims third-party administration (TPA) operations, where the volume of repeatable work is large. A significant portion of gains comes from Xceedance teammates continuously refining AI-enabled workflows — correcti
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom